Pharming Group N.V. (PHAR) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pharming Group N.V. (PHAR) has outperformed Wave Life Sciences (WVE) over the past year, losing 34.2% versus a loss of 50.8%. Over five years, PHAR leads with a +2.2% price change compared with -31.3% for WVE. Wave Life Sciences is the larger company by market cap ($697.6 million vs $683.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHAR | WVE |
|---|---|---|
| Share price | $9.65 | $3.54 |
| Market cap | $683.01M | $697.55M |
| 1-day change | -0.31% | +0.57% |
| YTD return | -45.39% | -79.18% |
| 1-year return | -34.22% | -50.76% |
| 5-year return | +2.22% | -31.26% |
| P/E ratio (TTM) | 74.23 | — |
| Forward P/E | 31.43 | — |
| EPS (TTM) | $0.13 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.34 | $21.73 |
| 52-week low | $9.59 | $3.43 |
| Distance from 52-week high | -54.78% | -83.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +255.96% | +410.17% |
| Average volume | 23.12K | 3.10M |
| Shares outstanding | 70.78M | 197.05M |
| Employees | 407 | 317 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHAR has outperformed WVE by 16.5 percentage points over the past year.
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Healthcare · Biotechnology · 407 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Healthcare · Biotechnology · 317 employees
PHAR vs WVE FAQ
Which is bigger, Pharming Group N.V. or Wave Life Sciences?
Wave Life Sciences (WVE) is larger, with a market capitalization of $697.55M compared with $683.01M for Pharming Group N.V. (PHAR).
Which stock has performed better over the past year, PHAR or WVE?
PHAR returned -34.22% over the past 12 months, compared with -50.76% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Pharming Group N.V. and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.